Empowered Patient Podcast

Dr. Mohammed Elamir, lead physician at Aviv Clinics, offers diagnostics and treatments for brain injuries such as PTSD, stroke, and traumatic brain injury and to address cognitive decline. After comprehensive physical and mental assessment, including brain scans, patients receive hyperbaric oxygen therapy and other therapies like psychotherapy and neurocognitive training. Individualized plans are designed to get to the root causes of neurological and cognitive issues and stimulate the growth of new cells and blood flow, even for patients with long-standing conditions.

Dr. Mo explains, "Our pre-assessment testing is a lot more rigorous than your kind of annual physical. We do three to five days of testing that can involve medical evaluations with the medical doctors and advanced blood work for different biomarkers for injury or inflammation. Two very specific brain scans that I think separate our assessment from most, and one is an MRI with DTI analysis. That is a microstructure analysis of the brain. So we can look at the nerve tracks running through the brain, how well-connected, and how dense they are."

"If somebody's approved for the treatment, they would undergo up to a 12-week treatment regimen involving hyperbaric oxygen therapy. And we can go into the details of that oxygen therapy, but in addition to that, they'll have other appointments, whether it's PT, psychological counseling, or neurocognitive training. And by the end of the 12 weeks, they should be feeling better, but objectively, we want to see why. We repeat the entire pre-treatment assessment at the end so we can have an objective comparison."

#AvivClinics #HBOT #Hyperbaricmedicine #PTSD #Stoke #Aging

Aviv-Clinics.com

Listen to the podcast here

Dr. Mohammed Elamir, lead physician at Aviv Clinics, offers diagnostics and treatments for brain injuries such as PTSD, stroke, and traumatic brain injury and to address cognitive decline. After comprehensive physical and mental assessment, including brain scans, patients receive hyperbaric oxygen therapy and other therapies like psychotherapy and neurocognitive training. Individualized plans are designed to get to the root causes of neurological and cognitive issues and stimulate the growth of new cells and blood flow, even for patients with long-standing conditions.

Dr. Mo explains, "Our pre-assessment testing is a lot more rigorous than your kind of annual physical. We do three to five days of testing that can involve medical evaluations with the medical doctors and advanced blood work for different biomarkers for injury or inflammation. Two very specific brain scans that I think separate our assessment from most, and one is an MRI with DTI analysis. That is a microstructure analysis of the brain. So we can look at the nerve tracks running through the brain, how well-connected, and how dense they are."

"If somebody's approved for the treatment, they would undergo up to a 12-week treatment regimen involving hyperbaric oxygen therapy. And we can go into the details of that oxygen therapy, but in addition to that, they'll have other appointments, whether it's PT, psychological counseling, or neurocognitive training. And by the end of the 12 weeks, they should be feeling better, but objectively, we want to see why. We repeat the entire pre-treatment assessment at the end so we can have an objective comparison."

#AvivClinics #HBOT #HyperbaricMedicine #PTSD #Stoke #Aging

Aviv-Clinics.com

Download the transcript here

Tomer Shussman, the Co-Founder and CEO of OneStep, is at the forefront of motion intelligence and gait analysis. OneStep provides a smartphone app that monitors movement and provides real-time data about gait patterns and changes over time. The system can predict and prevent conditions like falls, provide information about overall health, and reveal early warning signs for Parkinson's, Alzheimer's, and other aging-related diseases. Integrating OneStep's gait analysis data with Epic electronic health records allows healthcare providers to streamline documentation and leverage gait data to provide immediate actionable feedback to patients.

Tomer explains, "When we started OneStep, we started with physical therapy and rehabilitation, particularly after knee replacements, hip replacements, and injuries of all kinds. But since then, we now have customers and partners who work with us on fall prevention, essentially identifying and quantifying the risk of falling through gait analysis. Our partners work with us on using gait as a biofeedback tool for dosing the level of chemotherapy."

"We recently launched a cognitive decline score that measures and quantifies the cognitive impact on gait in cases like Parkinson's disease, Alzheimer's disease, ALS, and dementia by looking at the differences between conscious and unconscious gait. And this is just scratching the surface. These are all things that are already commercialized. We have so much more in the pipeline that we're currently researching."

"What we've been able to add to it is that we have customers and partners conducting a Timed Up and Go Test through OneStep. What we've been able to add to it from a clinical perspective is parameters like the base width - is the patient walking on a very wide base or a very narrow base, the step length, and the step length asymmetry."

#OneStep #GaitAnalysis #FallPrevention #Gait #RTM #RemoteTherapeuticMonitoring #SeniorLivingFacilities

OneStep.co

Listen to the podcast here

Tomer Shussman, the Co-Founder and CEO of OneStep, is at the forefront of motion intelligence and gait analysis. OneStep provides a smartphone app that monitors movement and provides real-time data about gait patterns and changes over time. The system can predict and prevent conditions like falls, provide information about overall health, and reveal early warning signs for Parkinson's, Alzheimer's, and other aging-related diseases. Integrating OneStep's gait analysis data with Epic electronic health records allows healthcare providers to streamline documentation and leverage gait data to provide immediate actionable feedback to patients.

Tomer explains, "When we started OneStep, we started with physical therapy and rehabilitation, particularly after knee replacements, hip replacements, and injuries of all kinds. But since then, we now have customers and partners who work with us on fall prevention, essentially identifying and quantifying the risk of falling through gait analysis. Our partners work with us on using gait as a biofeedback tool for dosing the level of chemotherapy."

"We recently launched a cognitive decline score that measures and quantifies the cognitive impact on gait in cases like Parkinson's disease, Alzheimer's disease, ALS, and dementia by looking at the differences between conscious and unconscious gait. And this is just scratching the surface. These are all things that are already commercialized. We have so much more in the pipeline that we're currently researching."

"What we've been able to add to it is that we have customers and partners conducting a Timed Up and Go Test through OneStep. What we've been able to add to it from a clinical perspective is parameters like the base width - is the patient walking on a very wide base or a very narrow base, the step length, and the step length asymmetry."

#OneStep #GaitAnalysis #FallPrevention #Gait #RTM #RemoteTherapeuticMonitoring #SeniorLivingFacilities

OneStep.co

Download the transcript here

Dr. Sherif Idriss is the CEO of Elastin Biosciences, a company focused on targeting aging-related diseases by restoring elastin, a key protein in the extracellular matrix that provides elasticity and resilience to organs and tissues. They are developing small molecule therapies for diseases linked to elastin deficiency, including Williams syndrome and abdominal aortic aneurysm. As elastin degrades over time due to aging, it leads to loss of tissue structural integrity and function, contributing to numerous age-related diseases.

Sherif explains, "One of the hallmarks of aging is the loss of the extracellular matrix, which is composed of several proteins. Collagen is quite famous, but also elastin is the other major protein that is responsible for the elasticity of the different organs. For example, in our skin, the loss of elastin is associated with us looking older and having all the aging signs and wrinkles on the skin. If you imagine that there are other organs inside that we don't visually see, then you have also the blood vessels, the lungs, a lot of the connective tissue. The extracellular matrix proteins and elastin itself are also aging in the same way and have their own form of damage one way or another. All of this contributes to aging and aging-related diseases as well."

"Another kind of disease is the category of rare diseases. In this case, we aim to target Williams syndrome, a rare disease characterized by a genetic partial deletion of around 26 genes. One of these genes is elastin itself, so some genetic material is still there, but there is not enough. We would like to try to push the elastin production up in Williams syndrome, and this would help rectify a lot of the disease issues, particularly when it comes to the cardiovascular system because Williams syndrome patients have quite a lot of issues with the cardiovascular system from birth and all through life."

#ElastinBiosciences #Aging #AgingRelatedDiseases #Elastin #WilliamsSyndrome

elastin-biosciences.com

Listen to the podcast here

Dr. Sherif Idriss is the CEO of Elastin Biosciences, a company focused on targeting aging-related diseases by restoring elastin, a key protein in the extracellular matrix that provides elasticity and resilience to organs and tissues. They are developing small molecule therapies for diseases linked to elastin deficiency, including Williams syndrome and abdominal aortic aneurysm. As elastin degrades over time due to aging, it leads to loss of tissue structural integrity and function, contributing to numerous age-related diseases.

Sherif explains, "One of the hallmarks of aging is the loss of the extracellular matrix, which is composed of several proteins. Collagen is quite famous, but also elastin is the other major protein that is responsible for the elasticity of the different organs. For example, in our skin, the loss of elastin is associated with us looking older and having all the aging signs and wrinkles on the skin. If you imagine that there are other organs inside that we don't visually see, then you have also the blood vessels, the lungs, a lot of the connective tissue. The extracellular matrix proteins and elastin itself are also aging in the same way and have their own form of damage one way or another. All of this contributes to aging and aging-related diseases as well."

"Another kind of disease is the category of rare diseases. In this case, we aim to target Williams syndrome, a rare disease characterized by a genetic partial deletion of around 26 genes. One of these genes is elastin itself, so some genetic material is still there, but there is not enough. We would like to try to push the elastin production up in Williams syndrome, and this would help rectify a lot of the disease issues, particularly when it comes to the cardiovascular system because Williams syndrome patients have quite a lot of issues with the cardiovascular system from birth and all through life."

#ElastinBiosciences #Aging #AgingRelatedDiseases #Elastin #WilliamsSyndrome

elastin-biosciences.com

Download the transcript here

Dr. Harven DeShield is the CEO and Co-Founder of Vivacelle Bio, which is developing a nanoparticle-based treatment called VBI-S to address the underlying causes of septic shock. The treatment works by efficiently redistributing nitric oxide to help regulate blood pressure and improve organ function, reducing the need for traditional vasopressor treatments. Vivacelle is also developing a product to help address hemorrhagic shock and minimize reperfusion injury.

Harven explains, "There are seven aspects to septic shock - actually eight. So, first, you have an infection. You have to have an infection, whether it is a bacterial, virus, or fungus. And then, eventually, they give you fluids—your blood pressure drops. And so, they try to correct that by giving you fluids. And when the fluids fail, then you transition from sepsis to septic shock."

"Then, you are also dealing with the fact that they put you on vasopressors once you get into septic shock. When they put you on vasopressors, that creates another whole realm of problems, which I can get into later. But, essentially, they have some serious toxicity effects, including reducing cardiac output. It causes cardiac arrhythmia and blood clots and can even lead somebody to go into hemorrhagic shock. So, you have the infection problems, you have the relative and absolute hypovolemia problem."

"Our product, for example, works within, and I'm using phase 2a - we see results in as little as 90 minutes, in terms of, at least, correcting the blood pressure. And it really can be very severe, and time is of the essence. There used to be something they called the "golden hour". This means you have an hour, depending on how low your blood pressure is. Now, some people call it the "platinum ten minutes".

#VivacelleBio #SepticShock #Sepsis #Hypovolemia #UrgentCareTreatment

vivicellebio.com

Listen to the podcast here

Dr. Harven DeShield is the CEO and Co-Founder of Vivacelle Bio, which is developing a nanoparticle-based treatment called VBI-S to address the underlying causes of septic shock. The treatment works by efficiently redistributing nitric oxide to help regulate blood pressure and improve organ function, reducing the need for traditional vasopressor treatments. Vivacelle is also developing a product to help address hemorrhagic shock and minimize reperfusion injury.

Harven explains, "There are seven aspects to septic shock - actually eight. So, first, you have an infection. You have to have an infection, whether it is a bacterial, virus, or fungus. And then, eventually, they give you fluids—your blood pressure drops. And so, they try to correct that by giving you fluids. And when the fluids fail, then you transition from sepsis to septic shock."

"Then, you are also dealing with the fact that they put you on vasopressors once you get into septic shock. When they put you on vasopressors, that creates another whole realm of problems, which I can get into later. But, essentially, they have some serious toxicity effects, including reducing cardiac output. It causes cardiac arrhythmia and blood clots and can even lead somebody to go into hemorrhagic shock. So, you have the infection problems, you have the relative and absolute hypovolemia problem."

"Our product, for example, works within, and I'm using phase 2a - we see results in as little as 90 minutes, in terms of, at least, correcting the blood pressure. And it really can be very severe, and time is of the essence. There used to be something they called the "golden hour". This means you have an hour, depending on how low your blood pressure is. Now, some people call it the "platinum ten minutes".

#VivacelleBio #SepticShock #Sepsis #Hypovolemia #UrgentCareTreatment

vivicellebio.com

Download the transcript here

Sandra Johnson, the Senior Vice President of Client Services at CliniComp, discusses the evolving landscape of electronic health records (EHRs) and the need for interoperability and customization to meet clinicians' needs. She emphasizes the importance of putting clinicians first and involving them in the software development process from the beginning to create a configurable and user-friendly system. There are multiple ways to use AI and automation to improve EHRs, including predictive analytics, automating routine tasks, and providing decision support for clinicians.

Sandra explains, "We are a 40-year-old company, so we've evolved a lot over the years to meet the growing needs of the healthcare industry. We originally started as a modular EMR system focused on the perinatal and critical care setting. We've continued to evolve over the years to offer inpatient solutions and now a full-service EHR solution suite. We continue to scale and grow to meet the evolving needs of the healthcare community and are happy to be able to provide a solution that is customized and driven by the clinicians' viewpoint."

"Well, there are always new trends that are arising. The latest buzz is around AI, and so it's a very complex environment with high acuity needs in the hospital setting. EHRs need to evolve to ensure that they're continuing to offer the solutions and services needed as that landscape continues to change. So, systems that are data-driven can provide that automation to provide time savings and operational efficiencies. It's not an easy task. It's a very complex environment, but a strong infrastructure and architecture that can scale to meet these needs is critical."

#Clinicomp #EHRSolutions #HealthcareInnovation #FutureHIT #IntegratedEHR #ElectronicHealthRecords #EHR #EMR

clinicomp.com

Listen to the podcast here

Sandra Johnson, the Senior Vice President of Client Services at CliniComp, discusses the evolving landscape of electronic health records (EHRs) and the need for interoperability and customization to meet clinicians' needs. She emphasizes the importance of putting clinicians first and involving them in the software development process from the beginning to create a configurable and user-friendly system. There are multiple ways to use AI and automation to improve EHRs, including predictive analytics, automating routine tasks, and providing decision support for clinicians.

Sandra explains, "We are a 40-year-old company, so we've evolved a lot over the years to meet the growing needs of the healthcare industry. We originally started as a modular EMR system focused on the perinatal and critical care setting. We've continued to evolve over the years to offer inpatient solutions and now a full-service EHR solution suite. We continue to scale and grow to meet the evolving needs of the healthcare community and are happy to be able to provide a solution that is customized and driven by the clinicians' viewpoint."

"Well, there are always new trends that are arising. The latest buzz is around AI, and so it's a very complex environment with high acuity needs in the hospital setting. EHRs need to evolve to ensure that they're continuing to offer the solutions and services needed as that landscape continues to change. So, systems that are data-driven can provide that automation to provide time savings and operational efficiencies. It's not an easy task. It's a very complex environment, but a strong infrastructure and architecture that can scale to meet these needs is critical."

#Clinicomp #EHRSolutions #HealthcareInnovation #FutureHIT #IntegratedEHR #ElectronicHealthRecords #EHR #EMR

clinicomp.com

Download the transcript here